Economic uncertainty remains a major concern in many industry sectors. For investors in well known companies like AstraZeneca (LON:AZN), the question is: where will prices go from here? AstraZeneca is part of an elite club of UK shares...
|Type||Buy / Hold / Sell|
|Year End 31st Dec||Unit||2017||2018||2019||2020||2021||2022E||2023E||CAGR / Avg|
|Diluted Normalised EPS|
|Op. Cashflow ps|
|Free Cashflow ps|
|Diluted Weighted Average Shares||m|
|Book Value ps|
|Leverage (ttm)||Total||- Intang||+ Pension|
|Cash / Assets|
Latest News & Insights for AZN
It's difficult to pick your own shares successfully – research consistently shows that more than half of retail investors in the UK and US who pick their own shares lose money. Even for skilful investors who buy a share and see it rise...
While the world wrestles with the impact of Covid, inflation and geopolitical strife, investors are naturally wondering what lies in store for some of the country's largest quoted companies, such as AstraZeneca (LON:AZN). AstraZeneca...
Buy, hold and sell recommendations from company analysts can be a useful signal about the sentiment around a stock. Examining the 'consensus' rating among brokers can give you a sense of whether the share is worth buying or not. Take A...
It has been a wild ride for some of the UK's biggest quoted companies over the past year. Economic uncertainty persists and the question on the minds of many investors is where the prices of stocks like Astrazeneca (LON:AZN) will go fr...
AstraZeneca PLC is a patient-focused pharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines. The Company is focused on various therapy areas, such as Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism (CVRM) and Respiratory & Immunology (R&I)), and Rare Disease. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 177 projects, of which 161 are in the clinical phase of development. Its key marketed oncology products include Tagrisso (osimertinib), Lynparza (olaparib), Imfinzi (durvalumab), Koselugo (selumetinib), Farxiga/ Forxiga (dapagliflozin), Roxadustat, Onglyza (saxagliptin) and others. The Company’s geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia.
- Leif Johansson NEC (69)
- Pascal Soriot CEO (61)
- Aradhana Sarin CFO (46)
- Jeffrey Pott CHO
- Katarina Ageborg EVP
- Jose Baselga EVP (60)
- Pam Cheng EVP (50)
- Ruud Dobber EVP
- David Fredrickson EVP
- Menelas Pangalos EVP
- Iskra Reic EVP
- Leon Wang EVP
- Adrian Kemp SEC
- Euan Ashley NED
- Diana Layfield NED
- Tony Mok NED
- Andreas Rummelt NED (64)
- Marcus Wallenberg NED (65)
- Philip Broadley NID
- Michel Demare NID (64)
- Deborah Eldracher NID (60)
- Sherilyn McCoy NID (62)
- Nazneen Rahman NID
Latest News for AZN
Upcoming Events for AZN
Q2 2022 AstraZeneca PLC Earnings Release
As of Today at 19:02 UTC, shares in AstraZeneca are trading at 10,754.00p. This share price information is delayed by 15 minutes.
Shares in AstraZeneca last closed at 10,754.00p and the price had moved by +23.02% over the past 365 days. In terms of relative price strength the AstraZeneca share price has outperformed the FTSE All Share Index by +26.95% over the past year.
The overall consensus recommendation for AstraZeneca is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The AstraZeneca dividend yield is 2.2% based on the trailing twelve month period.
Last year, AstraZeneca paid a total dividend of $2.86, and it currently has a trailing dividend yield of 2.2%. We do not have any data on when AstraZeneca is to next pay dividends.
We do not have data on when AstraZeneca is to next pay dividends. The historic dividend yield on AstraZeneca shares is currently 2.2%.
To buy shares in AstraZeneca you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 10,754.00p, shares in AstraZeneca had a market capitalisation of £166.63bn.
Here are the trading details for AstraZeneca:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: AZN
Based on an overall assessment of its quality, value and momentum AstraZeneca is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AstraZeneca is 11,191.50p. That is 4.07% above the last closing price of 10,754.00p.
Analysts covering AstraZeneca currently have a consensus Earnings Per Share (EPS) forecast of $6.64 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AstraZeneca. Over the past six months, its share price has outperformed the FTSE All Share Index by +34.5%.
As of the last closing price of 10,754.00p, shares in AstraZeneca were trading +15.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AstraZeneca PE ratio based on its reported earnings over the past 12 months is 18.03. The shares last closed at 10,754.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AstraZeneca's management team is headed by:
- Leif Johansson - NEC
- Pascal Soriot - CEO
- Aradhana Sarin - CFO
- Jeffrey Pott - CHO
- Katarina Ageborg - EVP
- Jose Baselga - EVP
- Pam Cheng - EVP
- Ruud Dobber - EVP
- David Fredrickson - EVP
- Menelas Pangalos - EVP
- Iskra Reic - EVP
- Leon Wang - EVP
- Adrian Kemp - SEC
- Euan Ashley - NED
- Diana Layfield - NED
- Tony Mok - NED
- Andreas Rummelt - NED
- Marcus Wallenberg - NED
- Philip Broadley - NID
- Michel Demare - NID
- Deborah Eldracher - NID
- Sherilyn McCoy - NID
- Nazneen Rahman - NID